Arvinas Announces Retirement of John Houston, Ph.D., Chairperson as Chief Executive Officer

Published: 2025-07-09 08:21:05 ET ARVN

Published on 07/09/2025 at 08:21

Arvinas, Inc. announced John Houston, Ph.D., Chairperson, Chief Executive Officer (CEO) and President at Arvinas, has informed the Board of Directors of his plans to retire from his role as CEO following a search for, and the appointment of, the Company?s new CEO. The Arvinas Board of Directors has begun a search for a new CEO, and Dr. Houston will remain Chairperson of Arvinas? Board of Directors upon retiring as President and CEO.

With more than 35 years of experience in the pharmaceutical and biotech industries, Dr. Houston joined Arvinas in January 2017 as President of Research and Development and Chief Scientific Officer responsible for leading the discovery, translational, and early clinical development research efforts. In September 2017, Dr. Houston was appointed President and CEO, and in 2023 he was named Arvinas? Chairperson.During his tenure as CEO, Dr. Houston has been instrumental in Arvinas?

success moving six programs into the clinic, reporting the results of the first positive pivotal Phase 3 trial for a PROTAC, and reporting for the first time that an orally administered PROTAC can achieve pharmacodynamic activity in the central nervous system.